Biogen Inc.

NASDAQ:BIIB

Drug Manufacturers - General

Healthcare
$251.41 -1.11%

-$2.21 today

Market cap
$37.16B
Beta
0.18
P/E (TTM)
21.1
EPS (TTM)
$9.32
52W Low $121.05High $205.97

Volume 1.14M

Average 1.17M

BIIB EBITDA Margin

EBITDA as a percentage of revenue.

Biogen Inc.NASDAQ: BIIB

EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026

EBITDA Margin narrows to 16.5%

EBITDA Margin was 16.5% in Q2 FY2026, down 25.5 pp from a year earlier. On a trailing-twelve-month basis it was 19.7%, down 14.2 pp year over year. Over 3 fiscal years it narrowed by 4.7 pp.

Context

  • EBITDA Margin widened in 1 of the last 3 fiscal years.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 26 analysts of 28.7% for the fiscal year ending Dec 2026, down from 30.0% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
16.5%-8.6 pp QoQ
Last fiscal yearDec 2025
30.0%-0.9 pp YoY
LTMJun 2026
19.7%-14.2 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-25.5 pp-8.5 pp+17.0 pp
1 year-0.9 pp-1.3 pp-0.4 pp
3 years-4.7 pp+4.8 pp+9.5 pp
5 years+5.4 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
30.0%
Year-over-year change
-0.9pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How BIIB compares with its peers on the latest reported figures

  • BIIB's LTM Jun 2026 EBITDA Margin of 19.7% is the 9th highest of the 11 companies compared; the peer median is 35.7%.
  • Its year-over-year change of -14.2 pp is the 9th highest of 11, against a peer median of -1.7 pp.
  • Over three fiscal years its change of -4.7 pp compares with a peer median of +6.0 pp.
BIIB Competitors Peer median
EBITDA Margin for BIIB and competitors
Company Period LTM level YoY 3-year change
LLYEli Lilly and CompanyLTM Jun 202654.4% +14.4 pp+18.3 pp
UTHRUnited Therapeutics CorporationLTM Jun 202653.1% -2.6 pp+3.4 pp
AMGNAmgen Inc.LTM Jun 202646.2% +0.7 pp-0.2 pp
VRTXVertex Pharmaceuticals IncorporatedLTM Sep 202637.4% -2.3 pp-9.4 pp
REGNRegeneron Pharmaceuticals, Inc.LTM Jun 202637.0% -1.1 pp-2.6 pp
AZNAstraZeneca PLCLTM Sep 202634.4% +3.4 pp+13.3 pp
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 202624.0% +30.9 pp+106.3 pp
PFEPfizer Inc.LTM Jun 202621.2% -10.4 pp-13.7 pp
BIIBBiogen Inc.LTM Jun 202619.7% -14.2 pp-4.7 pp
PTCTPTC Therapeutics, Inc.LTM Jun 202617.2% -30.5 pp+103.9 pp
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026-49.3% -33.5 pp+8.7 pp
Peer median (excluding BIIB) 35.7%-1.7 pp+6.0 pp

Competitors are the stored peer set for BIIB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue10.98B10.17B9.84B9.68B9.81B
Cost of Revenue2.11B2.28B2.53B2.31B2.9B
Gross Profit8.87B7.9B7.3B7.37B6.91B
Gross Margin80.8%77.6%74.2%76.1%70.5%
Research & Development3.4B2.6B2.7B2.49B1.95B
Selling, General & Admin2.68B2.41B2.5B2.39B2.43B
Operating Expenses6.08B5.01B5.2B4.88B5.04B
Depreciation & Amortization487.7M518.4M494.8M673.2M779.9M
EBITDA3.92B3.54B2.38B3B2.95B
EBITDA Margin35.7%34.8%24.2%31.0%30.0%
Operating Income2.79B2.89B2.1B2.49B1.88B
Operating Margin25.4%28.4%21.3%25.7%19.1%
Interest Income11M89.3M276.5M67.6M87.8M
Interest Expense253.6M246.6M246.9M250.3M246M
Other Income / Expenses(1.01B)705.3M(800.5M)(584.3M)(476M)
Income Before Tax1.78B3.59B1.3B1.91B1.4B
Pre-Tax Margin16.2%35.3%13.2%19.7%14.3%
Income Tax Expense52.5M632.8M135.3M273.8M108.11M
Net Income1.56B3.05B1.16B1.63B1.29B
Net Margin14.2%29.9%11.8%16.9%13.2%
EPS (Basic)10.4420.978.0211.208.85
EPS (Diluted)10.4020.877.9711.198.83
Weighted Avg Shares149.1M145.3M144.7M145.7M146.7M
Weighted Avg Shares (Diluted)149.6M146M145.6M145.9M146.7M

Biogen Inc.

NASDAQ:BIIB

Intrinsic Alpha fair value

Locked

Current Price

$251.41

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.